High Serum A beta and Vascular Risk Factors in First-Degree Relatives of Alzheimer's Disease Patients


Abdullah, L; Luis, C; Paris, D; Ait-Ghezala, G; Mouzon, B; Allen, E; Parrish, J; Mullan, MA; Ferguson, S; Wood, M; Crawford, F; Mullan, M; (2009) High Serum A beta and Vascular Risk Factors in First-Degree Relatives of Alzheimer's Disease Patients. Molecular medicine (Cambridge, Mass), 15 (3-4). pp. 95-100. ISSN 1076-1551 DOI: https://doi.org/10.2119/molmed.2008.00118

[img]
Preview
Other - Published Version
License:

Download (78kB) | Preview

Abstract

The main objective of this study was to determine whether elevated blood beta-amyloid (A beta) levels among the first-degree relatives of patients with Alzheimer's Disease (AD) are associated with vascular risk factors of AD. Serum A beta was measured in samples from 197 cognitively normal first-degree relatives of patients with AD-like dementia, Study participants were recruited as part of an ancillary study of the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT subpopulation). The ADAPT subpopulation was found to be similar in age, sex, and ethnicity to another cognitively normal cohort (n = 98). Using cross-sectional analyses, we examined the association of A beta with blood pressure, lipid levels, apolipoprotein E genotypes, and the use of prescribed medication to treat vascular risk factors in the ADAPT subpopulation. A beta(1-40) was positively associated with age, use of antihypertensives, and serum creatinine, and we observed a marginal negative interaction on A beta(1-40) associated with systolic blood pressure and use of antihypertensives. Serum A beta(1-42) was associated with statin use and a positive correlation of A beta(1-42) with HDL was observed among statin nonusers. These findings suggest that high A beta in the periphery among the family history-enriched cohorts may be due to enrichment of vascular risk factors and may reflect presymptomatic AD pathology. It remains to be determined whether the association of A beta with medications used for treating vascular risk factors indicates prevention of AD. Longitudinal evaluation of blood A beta in this cohort will provide a better understanding of the significance of this association in AD etiology. (C) 2009 The Feinstein Institute for Medical Research, www.feinsteininstitute.org Online address: http://www.molmed.org doi: 10.2119/molmed.2008.00118

Item Type: Article
Keywords: mild cognitive impairment, high-density-lipoproteins, plasma a-beta-42, epsilon-4 allele, blood-pressure, dementia, protein, cohort, population, onset, Aged, Aged, 80 and over, Alzheimer Disease, blood, pathology, prevention & control, Amyloid beta-Protein, blood, Anti-Inflammatory Agents, Non-Steroidal, therapeutic use, Blood Vessels, metabolism, pathology, Family, Female, Humans, Peptide Fragments, blood, Risk Factors
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Medical Statistics
PubMed ID: 19081767
Web of Science ID: 276043500005
URI: http://researchonline.lshtm.ac.uk/id/eprint/3891

Statistics


Download activity - last 12 months
Downloads since deposit
1Download
308Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item